EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder
November 06, 2023EG 427 today reports positive preclinical results from a dose escalation study of its gene therapy product EG110A for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). The data represents a pivotal milestone and paves the way for an Investigational New Drug (IND) application and initiation of the first clinical study of EG110A in early 2024.
Access full Press Release in English and in French.